In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last Friday at $117.61.

According to TipRanks, Flynn is a 4-star analyst with an average return of 6.0% and a 56.98% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Merck & Company.

In addition to Morgan Stanley, BioNTech SE also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued on February 4. However, on January 27, J.P. Morgan maintained a Hold rating on BioNTech SE (NASDAQ: BNTX).

The company has a one-year high of $131.49 and a one-year low of $76.53. Currently, BioNTech SE has an average volume of 822.6K.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.